Evaluation of a PSMA-targeted BNF nanoparticle construct

Babak Behnam Azad, Sangeeta Ray, Mrudula Pullambhatla, Silvia Lacerda, Catherine Foss, Yuchuan Wang, Robert Ivkov, Martin Gilbert Pomper

Research output: Contribution to journalArticle

Abstract

Early detection enables improved prognosis for prostate cancer (PCa). A promising target for imaging and therapy of PCa is the prostate-specific membrane antigen (PSMA), which exhibits both expression within the epithelium of PCa cells, and becomes internalized upon ligand binding. Here we report the synthesis of a PSMA-targeted bionized nanoferrite (BNF) nanoparticle and its biological evaluation in an experimental model of PCa. The BNF nanoparticle formulation exhibits properties conducive to targeted imaging such as stealth, prolonged circulation time and enhanced clearance from non-target sites. Optical imaging of the targeted BNF in vivo indicates preferential accumulation in PSMA+ tumors 4 h post-injection, suggesting target specificity. On the other hand, non-targeted nanoparticles exhibit lower uptake with similar accumulation in both PSMA+ and PSMA- tumors indicating tumor access without preferential accumulation. Imaging with single photon emission computed tomography (SPECT) and biodistribution studies of a modified construct indicate highest tumor accumulation at 48 h post-injection [4.3 ± 0.4 percentage injected dose per gram of tissue (%ID g-1)], with tumor/blood and tumor/muscle ratios of 7.5 ± 2.4 and 11.6 ± 1.2 %ID g-1, respectively. Ex vivo fluorescence microscopy, Prussian blue staining, immunohistochemistry and biodistribution studies confirm enhanced nanoparticle uptake in PSMA+ tumors compared to those not expressing PSMA. The BNF nano-formulation described is promising for PSMA-targeted imaging applications in vivo. This journal is

Original languageEnglish (US)
Pages (from-to)4432-4442
Number of pages11
JournalNanoscale
Volume7
Issue number10
DOIs
StatePublished - Mar 14 2015

Fingerprint

Antigens
Tumors
Nanoparticles
Membranes
Imaging techniques
Single photon emission computed tomography
human glutamate carboxypeptidase II
Fluorescence microscopy
Muscle
Blood
Ligands
Tissue

ASJC Scopus subject areas

  • Materials Science(all)

Cite this

Evaluation of a PSMA-targeted BNF nanoparticle construct. / Behnam Azad, Babak; Ray, Sangeeta; Pullambhatla, Mrudula; Lacerda, Silvia; Foss, Catherine; Wang, Yuchuan; Ivkov, Robert; Pomper, Martin Gilbert.

In: Nanoscale, Vol. 7, No. 10, 14.03.2015, p. 4432-4442.

Research output: Contribution to journalArticle

Behnam Azad, Babak ; Ray, Sangeeta ; Pullambhatla, Mrudula ; Lacerda, Silvia ; Foss, Catherine ; Wang, Yuchuan ; Ivkov, Robert ; Pomper, Martin Gilbert. / Evaluation of a PSMA-targeted BNF nanoparticle construct. In: Nanoscale. 2015 ; Vol. 7, No. 10. pp. 4432-4442.
@article{840d91ccbbb54ce6a7b2e3f4b1e61dd1,
title = "Evaluation of a PSMA-targeted BNF nanoparticle construct",
abstract = "Early detection enables improved prognosis for prostate cancer (PCa). A promising target for imaging and therapy of PCa is the prostate-specific membrane antigen (PSMA), which exhibits both expression within the epithelium of PCa cells, and becomes internalized upon ligand binding. Here we report the synthesis of a PSMA-targeted bionized nanoferrite (BNF) nanoparticle and its biological evaluation in an experimental model of PCa. The BNF nanoparticle formulation exhibits properties conducive to targeted imaging such as stealth, prolonged circulation time and enhanced clearance from non-target sites. Optical imaging of the targeted BNF in vivo indicates preferential accumulation in PSMA+ tumors 4 h post-injection, suggesting target specificity. On the other hand, non-targeted nanoparticles exhibit lower uptake with similar accumulation in both PSMA+ and PSMA- tumors indicating tumor access without preferential accumulation. Imaging with single photon emission computed tomography (SPECT) and biodistribution studies of a modified construct indicate highest tumor accumulation at 48 h post-injection [4.3 ± 0.4 percentage injected dose per gram of tissue ({\%}ID g-1)], with tumor/blood and tumor/muscle ratios of 7.5 ± 2.4 and 11.6 ± 1.2 {\%}ID g-1, respectively. Ex vivo fluorescence microscopy, Prussian blue staining, immunohistochemistry and biodistribution studies confirm enhanced nanoparticle uptake in PSMA+ tumors compared to those not expressing PSMA. The BNF nano-formulation described is promising for PSMA-targeted imaging applications in vivo. This journal is",
author = "{Behnam Azad}, Babak and Sangeeta Ray and Mrudula Pullambhatla and Silvia Lacerda and Catherine Foss and Yuchuan Wang and Robert Ivkov and Pomper, {Martin Gilbert}",
year = "2015",
month = "3",
day = "14",
doi = "10.1039/c4nr06069e",
language = "English (US)",
volume = "7",
pages = "4432--4442",
journal = "Nanoscale",
issn = "2040-3364",
publisher = "Royal Society of Chemistry",
number = "10",

}

TY - JOUR

T1 - Evaluation of a PSMA-targeted BNF nanoparticle construct

AU - Behnam Azad, Babak

AU - Ray, Sangeeta

AU - Pullambhatla, Mrudula

AU - Lacerda, Silvia

AU - Foss, Catherine

AU - Wang, Yuchuan

AU - Ivkov, Robert

AU - Pomper, Martin Gilbert

PY - 2015/3/14

Y1 - 2015/3/14

N2 - Early detection enables improved prognosis for prostate cancer (PCa). A promising target for imaging and therapy of PCa is the prostate-specific membrane antigen (PSMA), which exhibits both expression within the epithelium of PCa cells, and becomes internalized upon ligand binding. Here we report the synthesis of a PSMA-targeted bionized nanoferrite (BNF) nanoparticle and its biological evaluation in an experimental model of PCa. The BNF nanoparticle formulation exhibits properties conducive to targeted imaging such as stealth, prolonged circulation time and enhanced clearance from non-target sites. Optical imaging of the targeted BNF in vivo indicates preferential accumulation in PSMA+ tumors 4 h post-injection, suggesting target specificity. On the other hand, non-targeted nanoparticles exhibit lower uptake with similar accumulation in both PSMA+ and PSMA- tumors indicating tumor access without preferential accumulation. Imaging with single photon emission computed tomography (SPECT) and biodistribution studies of a modified construct indicate highest tumor accumulation at 48 h post-injection [4.3 ± 0.4 percentage injected dose per gram of tissue (%ID g-1)], with tumor/blood and tumor/muscle ratios of 7.5 ± 2.4 and 11.6 ± 1.2 %ID g-1, respectively. Ex vivo fluorescence microscopy, Prussian blue staining, immunohistochemistry and biodistribution studies confirm enhanced nanoparticle uptake in PSMA+ tumors compared to those not expressing PSMA. The BNF nano-formulation described is promising for PSMA-targeted imaging applications in vivo. This journal is

AB - Early detection enables improved prognosis for prostate cancer (PCa). A promising target for imaging and therapy of PCa is the prostate-specific membrane antigen (PSMA), which exhibits both expression within the epithelium of PCa cells, and becomes internalized upon ligand binding. Here we report the synthesis of a PSMA-targeted bionized nanoferrite (BNF) nanoparticle and its biological evaluation in an experimental model of PCa. The BNF nanoparticle formulation exhibits properties conducive to targeted imaging such as stealth, prolonged circulation time and enhanced clearance from non-target sites. Optical imaging of the targeted BNF in vivo indicates preferential accumulation in PSMA+ tumors 4 h post-injection, suggesting target specificity. On the other hand, non-targeted nanoparticles exhibit lower uptake with similar accumulation in both PSMA+ and PSMA- tumors indicating tumor access without preferential accumulation. Imaging with single photon emission computed tomography (SPECT) and biodistribution studies of a modified construct indicate highest tumor accumulation at 48 h post-injection [4.3 ± 0.4 percentage injected dose per gram of tissue (%ID g-1)], with tumor/blood and tumor/muscle ratios of 7.5 ± 2.4 and 11.6 ± 1.2 %ID g-1, respectively. Ex vivo fluorescence microscopy, Prussian blue staining, immunohistochemistry and biodistribution studies confirm enhanced nanoparticle uptake in PSMA+ tumors compared to those not expressing PSMA. The BNF nano-formulation described is promising for PSMA-targeted imaging applications in vivo. This journal is

UR - http://www.scopus.com/inward/record.url?scp=84924011933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924011933&partnerID=8YFLogxK

U2 - 10.1039/c4nr06069e

DO - 10.1039/c4nr06069e

M3 - Article

VL - 7

SP - 4432

EP - 4442

JO - Nanoscale

JF - Nanoscale

SN - 2040-3364

IS - 10

ER -